Neurocrine Biosciences (NBIX) Capital Leases (2010 - 2017)

Neurocrine Biosciences has reported Capital Leases for 8 years, with the latest figure at $544000.0 in Q1 2017.

• For the quarter ending Q1 2017, Capital Leases fell 32.76% year-over-year to $544000.0; the trailing twelve-month figure through Mar 2017 stood at $544000.0 (down 32.76% YoY), and the FY2016 full-year result was $617000.0, down 60.32% from the prior year.
• Capital Leases for Q1 2017 stood at $544000.0, down from $617000.0 in the prior quarter.
• The five-year high for Capital Leases was $3.0 million in Q1 2013, with the low at $544000.0 in Q1 2017.
• Historically, Capital Leases has averaged $1.8 million across 5 years, with a median of $2.1 million in 2015.
• Annual changes were most pronounced in 2013 — Capital Leases soared 32.63% — and 2016, when it sank 61.22%.
• Neurocrine Biosciences' Capital Leases stood at $2.7 million in 2013, then retreated by 17.5% to $2.2 million in 2014, then fell by 29.67% to $1.6 million in 2015, then slumped by 60.32% to $617000.0 in 2016, then declined by 11.83% to $544000.0 in 2017.
• The last three Capital Leases figures came in at $544000.0 (Q1 2017), $617000.0 (Q4 2016), and $649000.0 (Q3 2016), per Business Quant data.